Mode
Text Size
Log in / Sign up
N/A Completed N=24 Treatment

Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent

Ureteral Obstruction
Source: ClinicalTrials.gov NCT00166361 ↗
Enrolled (actual)
24
Serious AEs
58.3%
Results posted
Jul 2014
Primary outcomePrimary: Mean Stent Dwell Time — 17; 3.97 months

Summary

The purpose of this study is to evaluate the safety and efficacy of the Memokath 051 ureteral stent as a long-term temporary and minimally invasive means of providing ureteral drainage in the setting of malignant extrinsic ureteral obstruction secondary to inoperable abdominal or pelvic malignancies. Up to 15 adults who have extrinsic ureteral obstruction secondary to an inoperable abdominal or pelvic malignancy and need ureteral stent drainage will undergo outpatient placement of the ureteral stent. Ongoing monitoring will continue for as long as the stent is in place.

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Stent Dwell Time
17; 3.97

Eligibility Criteria

Inclusion Criteria

  • Presence of extrinsic ureteral obstruction
  • secondary to inoperable pelvic or abdominal malignancy or
  • secondary to changes caused by surgery, chemotherapy, or radiation for pelvic and/or abdominal malignancies who have had >2 standard double J stent exchanges with no prospect of being stent-free
  • Life expectancy greater than 4 months
  • Adult patient (18 years of age or older)
  • Preoperative medical examination clearing the patient for general anesthesia
  • No active urinary tract infection by urinalysis and urine culture.

Exclusion Criteria

  • Ureteral obstruction of a benign or intrinsic etiology
  • Lower urinary tract abnormality precluding cystoscopic stent placement
  • Patients with a solitary kidney
  • Patients not willing or unable to receive their post-operative follow-up at the Mayo Clinic in Rochester, Minnesota
  • Pregnant female patient.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00166361). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search